|
gptkbp:instanceOf
|
antipsychotic medication
|
|
gptkbp:ATCCode
|
gptkb:N05AH02
|
|
gptkbp:bioavailability
|
60-70%
|
|
gptkbp:brand
|
gptkb:Denzapine
gptkb:FazaClo
gptkb:Versacloz
gptkb:Zaponex
gptkb:Clozaril
|
|
gptkbp:CASNumber
|
gptkb:5786-21-0
|
|
gptkbp:contraindication
|
paralytic ileus
uncontrolled epilepsy
severe central nervous system depression
history of clozapine-induced agranulocytosis
hypersensitivity to clozapine
|
|
gptkbp:discoveredBy
|
gptkb:Wander_AG
|
|
gptkbp:discoveredIn
|
1958
|
|
gptkbp:drugClass
|
dibenzodiazepine derivative
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:FDAApproved
|
1989
|
|
gptkbp:hasMolecularFormula
|
C18H19ClN4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Clozapine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
antagonist at histamine H1 receptors
antagonist at serotonin 5-HT2A receptors
antagonist at muscarinic receptors
antagonist at adrenergic receptors
antagonist at dopamine D2 receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
C (US)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:requiresMonitoring
|
regular blood tests for white blood cell count
|
|
gptkbp:riskManagementProgram
|
gptkb:REMS_(Risk_Evaluation_and_Mitigation_Strategy)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
constipation
weight gain
seizures
myocarditis
sedation
tachycardia
agranulocytosis
hypersalivation
|
|
gptkbp:synonym
|
8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
treatment-resistant schizophrenia
reducing risk of recurrent suicidal behavior in schizophrenia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:CPZ
gptkb:N05AH
gptkb:13587-41-6
gptkb:P41143
|
|
gptkbp:bfsLayer
|
8
|